Analyst Price Target is $19.00
▲ +705.08% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Ikena Oncology in the last 3 months. The average price target is $19.00, with a high forecast of $22.00 and a low forecast of $16.00. The average price target represents a 705.08% upside from the last price of $2.36.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Ikena Oncology.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.